NASDAQ · MDCXW
Healthcare · Biotechnology
$0.33
Up+$0.01 (+2.97%)
Updated Aug 28, 2026, 3:14 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 7 trading sessions · Daily adjusted prices
MDCXW closed at $0.33 after 7 trading sessions, up 6.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 11, 2026 | $0.3302 | $0.3302 | $0.3302 | $0.3302 | 210.8 |
| Aug 7, 2026 | $0.44 | $0.44 | $0.44 | $0.44 | 100 |
| Aug 6, 2026 | $0.57 | $0.57 | $0.435 | $0.435 | 2.68K |
| Aug 5, 2026 | $0.3101 | $0.505 | $0.3101 | $0.505 | 745.41 |
| Aug 3, 2026 | $0.4387 | $0.50 | $0.4387 | $0.50 | 1.96K |
| Jul 31, 2026 | $0.4999 | $0.4999 | $0.4999 | $0.4999 | 130 |
| Jul 30, 2026 | $0.31 | $0.31 | $0.31 | $0.31 | 121.23 |
The latest Smart Investors Daily articles mentioning MDCXW.
MDCXW research
Company profile and research snapshot.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Jul 18, 2026
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study for Teverelix, reporting that the revised protocol had received Institutional Review Board approval and had been accepted by the US Food and Drug Administration subject to operational...
Yahoo · Jul 17, 2026
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to discuss the company's receipt of written FDA feedback and central Institutional Review Board (IRB) approval, with modifications, for its optimized Phase 2 clinical trial evaluating Teverelix® in men following a first episode of acute urinary retention (AUR). Bokhari said the randomized, double-blind, placebo-controlled, multicenter study, designated ANT-2111-02, will enroll approximately 126 patients to evaluate the effects of Teverelix DP, a long-acting GnRH antagonist, on prostate volume and urinary function after an initial episode of AUR. The FDA provided seven recommendations related to protocol implementation, safety monitoring, and study documentation, including updates to contraception reporting, injection-site blinding, alpha-blocker therapy tracking, race data collection, and clarification of a secondary endpoint. Importantly, Bokhari said the company believes the FDA's comments are operational in nature and can be addressed through protocol amendments without changing the study's scientific rationale, patient population, treatment arms, primary endpoint, or planned interim analysis. Medicus is now working with its regulatory, clinical, and contract research partners to incorporate both the FDA and IRB recommendations, finalize participating clinical sites, and complete the remaining start-up activities ahead of patient enrollment. Management believes the regulatory feedback represents another important milestone in advancing Teverelix as a potential treatment for men experiencing acute urinary retention associated with enlarged prostate disease. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Teverelix #ClinicalTrials #FDA #Biotech #Phase2 #Urology #DrugDevelopment #HealthcareInnovation #PharmaNews
Yahoo · Jun 22, 2026
Company’s presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome ProgramPHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it wi
Yahoo · Jun 20, 2026
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory package designed to support the launch of a Phase 2b clinical study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk. Speaking with Proactive, chief medical...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDCXW.
No results
No recent SID articles mention MDCXW.
